LIMITED-SAMPLING MODELS FOR ANTICANCER AGENTS

Pharmacokinetic parameters of antineoplastic drugs are usually generat ed from concentration/time profiles obtained after multiple venipunctu res. With limited-sampling models (LSM) this number can be reduced to between one and three timed plasma samples. LSMs may facilitate popula tion pharmacokinetic/pharmacodynamic studies, which eventually may lea d to a dosing strategy based on the characteristics of the individual patient. In this article, the development, validation and application of several LSMs reported in the literature are reviewed.